Publication Name	World Journal of Gastroenterology
Manuscript ID	79932
Country	India

Received	2022-09-12 11:06
Peer-Review Started	2022-09-12 11:07
First Decision by Editorial Office Director	2022-09-29 21:02
Return for Revision	2022-09-29 21:02
Revised	2022-10-07 10:10
Publication Fee Transferred
Second Decision by Editor	2022-11-16 03:16
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2022-11-17 23:00
Articles in Press	2022-11-17 23:00
Edit the Manuscript by Language Editor	2022-11-10 18:42
Typeset the Manuscript	2022-11-23 10:03
Publish the Manuscript Online	2022-12-02 09:49

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Evidence Review
Article Title	COVID-19 drug-induced liver injury: A recent update of the literature
Manuscript Source	Invited Manuscript
All Author List	Lekha Saha, Soumya Vij and Kajal Rawat
ORCID	Author(s) ORCID Number Lekha Saha http://orcid.org/0000-0001-5925-7159
Funding Agency and Grant Number
Corresponding Author	Lekha Saha, MBBS, MD, MNAMS, Full Professor, Professor, Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. lekhasaha@rediffmail.com
Key Words	Liver injury; COVID-19; Anti-COVID drugs; Mechanisms; Clinical evidences
Core Tip	Liver damage is cited as the most frequent clinical extrapulmonary manifestation in a number of coronavirus disease 2019 (COVID-19) clinical trials. Herein, we summarized the available clinical data concerning liver injury during COVID-19. Transaminases and bilirubin levels were high in a significant majority of patients; however, the exact cause of liver damage is not entirely clear. A worse clinical course of COVID-19 may be associated with severe liver enzyme abnormalities. However, it is impossible to rule out a number of additional cofactors (drug-induced liver damage, an inflammatory response to an infection, hypoxic hepatitis, or underlying liver disease).
Publish Date	2022-12-02 09:49
Citation	Saha L, Vij S, Rawat K. COVID-19 drug-induced liver injury: A recent update of the literature. World J Gastroenterol 2022; 28(45): 6314-6327
URL	https://www.wjgnet.com/1007-9327/full/v28/i45/6314.htm
DOI	https://dx.doi.org/10.3748/wjg.v28.i45.6314

Full Article (PDF)	WJG-28-6314.pdf
Full Article (Word)	WJG-28-6314.docx
Manuscript File	79932_Auto_Edited-LM.docx
Answering Reviewers	79932-Answering reviewers.pdf
Audio Core Tip	79932-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	79932-Conflict-of-interest statement.pdf
Copyright License Agreement	79932-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	79932-Language certificate.pdf
Peer-review Report	79932-Peer-review(s).pdf
Scientific Misconduct Check	79932-Bing-Wang JJ-2.png
Scientific Editor Work List	79932-Scientific editor work list.pdf
CrossCheck Report	79932-CrossCheck report.pdf